ALLK - Allakos Data And Other News: The Good Bad And Ugly Of Biopharma
Allakos Reports Encouraging Data for Antolimab
Allakos (ALLK) announced that it has received positive response from Phase 1 trial of its lead drug candidate antolimab. Phase 1 trial is an open label study designed to evaluate the lead drug candidate in seven patients suffering from moderate to severe gastrointestinal symptoms and elevated mast cells associated with mast cell gastrointestinal disease.
The results showed that six months of treatment brought about average reduction of 64 percent in Total Symptom Score. This finding corroborated the effects found during the Phase 2 ENIGMA study. The company is currently